KALA BIO, Inc.
KALA
Rank in Stocks
#30844
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the... Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Share Price
$0.75
Last synced: 2026-07-31
Market Cap
$14.50M
Change (1 day)
2.78%
Change (1 year)
-98.42%
Country
US
Trade KALA BIO, Inc. (KALA)
Category
Healthcare
Revenue for KALA BIO, Inc. (KALA)
Revenue in Oct 2026 TTM: 0
According to KALA BIO, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for KALA BIO, Inc. from 2026 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
